<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04487860</url>
  </required_header>
  <id_info>
    <org_study_id>AS012-20-01</org_study_id>
    <nct_id>NCT04487860</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo</brief_title>
  <official_title>A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Global FZE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Global FZE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, placebo-controlled, phase II study. The study will be
      performed as a multicenter, multinational study. I
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in Vitiligo Area Scoring Index score</measure>
    <time_frame>Week 24</time_frame>
    <description>Vitiligo Area Scoring Index score: numeric score that can range from 0 to 100, with higher VASI scores denoting poorer the disease state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Vitiligo Extent Score</measure>
    <time_frame>Week 24</time_frame>
    <description>Natural distribution of vitiligo on body reﬂecting 6 different degrees of involvement (1 percent, 5 percent, 10 percent, 25 percent, 50 percent, 75 percent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Vitiligo Impact Patient scale</measure>
    <time_frame>Week 24</time_frame>
    <description>subjects will be asked to complete a questionnaire to assess the burden experienced by individuals affected. Summary scores range from 0 to 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment scores</measure>
    <time_frame>Week 52</time_frame>
    <description>Score 0=no involvement or Score 1=limited extent with at least 2-point reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change, from baseline, in Dermatology Life Quality Index</measure>
    <time_frame>Week 52</time_frame>
    <description>The DLQI scores are based on the response from the patient. Each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0.
The higher the score, the more quality of life is impaired OR lower scores indicate better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Non-segmental Vitiligo</condition>
  <arm_group>
    <arm_group_label>AS012 dose regimen I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AS012 dose regimen II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AS012 dose regimen III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AS012 dose regimen IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS012</intervention_name>
    <description>oral administration</description>
    <arm_group_label>AS012 dose regimen I</arm_group_label>
    <arm_group_label>AS012 dose regimen II</arm_group_label>
    <arm_group_label>AS012 dose regimen III</arm_group_label>
    <arm_group_label>AS012 dose regimen IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent.

          2. Male or female ≥ 18 years of age at time of screening

          3. Stable (without new patches ≥ 1 year) or unstable (with new patches for the last 1
             year) vitiligo

          4. VASI of ≥ 4 at screening and baseline

        Exclusion Criteria:

          1. Segmental vitiligo, focal, or mixed Vitiligo

          2. Subjects who have high risk of suicidality at the Screening assessment based on
             Investigator's judgment

          3. History of alcohol or drug abuse in the previous 2 years

          4. Subjects who were submitted to melanocyte transfer

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head Clinical Development</last_name>
    <phone>912266455645</phone>
    <email>clinical.trials@sparcmail.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 25, 2020</last_update_submitted>
  <last_update_submitted_qc>July 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

